TR201907240T4 - Bir anti cd20 antikorunun bir btk inhibitörü ile kombinasyon tedavisi. - Google Patents

Bir anti cd20 antikorunun bir btk inhibitörü ile kombinasyon tedavisi. Download PDF

Info

Publication number
TR201907240T4
TR201907240T4 TR2019/07240T TR201907240T TR201907240T4 TR 201907240 T4 TR201907240 T4 TR 201907240T4 TR 2019/07240 T TR2019/07240 T TR 2019/07240T TR 201907240 T TR201907240 T TR 201907240T TR 201907240 T4 TR201907240 T4 TR 201907240T4
Authority
TR
Turkey
Prior art keywords
antibody
combination therapy
btk inhibitor
therapy
afucosylated
Prior art date
Application number
TR2019/07240T
Other languages
English (en)
Inventor
Klein Christian
Toshio Yoshizawa
Tomoko Yasuhiro
Original Assignee
Hoffmann La Roche
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Ono Pharmaceutical Co filed Critical Hoffmann La Roche
Publication of TR201907240T4 publication Critical patent/TR201907240T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Mevcut buluş, kanser tedavisi yönelik olarak afukozile bir anti-CD20 antikorunun bir BTK inhibitörü ile birlikte kombinasyon tedavisiyle, özellikle CD20 eksprese eden kanserlere yönelik afukozile bir insanlaştırılmış B-Ly1 antikoru ve bir BTK inhibitörünün kombinasyon tedavisiyle ilgilidir.
TR2019/07240T 2013-11-07 2014-11-04 Bir anti cd20 antikorunun bir btk inhibitörü ile kombinasyon tedavisi. TR201907240T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13192006 2013-11-07

Publications (1)

Publication Number Publication Date
TR201907240T4 true TR201907240T4 (tr) 2019-06-21

Family

ID=49552219

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/07240T TR201907240T4 (tr) 2013-11-07 2014-11-04 Bir anti cd20 antikorunun bir btk inhibitörü ile kombinasyon tedavisi.

Country Status (21)

Country Link
US (2) US20150125446A1 (tr)
EP (1) EP3066126B1 (tr)
JP (1) JP6478989B2 (tr)
KR (1) KR101874215B1 (tr)
CN (3) CN105792846A (tr)
AR (1) AR098328A1 (tr)
AU (1) AU2014345712B2 (tr)
BR (1) BR112016010271A2 (tr)
CA (1) CA2926893C (tr)
ES (1) ES2728350T3 (tr)
HK (1) HK1222803A1 (tr)
IL (1) IL244960B (tr)
MX (1) MX2016005801A (tr)
MY (1) MY178726A (tr)
NZ (1) NZ718792A (tr)
PH (1) PH12016500839A1 (tr)
PL (1) PL3066126T3 (tr)
RU (1) RU2727650C2 (tr)
TR (1) TR201907240T4 (tr)
TW (1) TWI524899B (tr)
WO (1) WO2015067586A2 (tr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080513A1 (es) 2010-03-12 2012-04-11 Inmunogen Inc Moleculas de union cd37 y sus inmunoconjugados
TWI535716B (zh) 2010-05-31 2016-06-01 Ono Pharmaceutical Co Purine ketone derivatives
NZ626750A (en) 2011-11-29 2015-08-28 Ono Pharmaceutical Co Purinone derivative hydrochloride
US9416131B2 (en) 2014-03-25 2016-08-16 Ono Pharmaceutical Co., Ltd. Prophylactic agent and/or therapeutic agent for diffuse large B-cell lymphoma
PT3262071T (pt) * 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
EP3281943B1 (en) 2015-04-09 2023-06-28 ONO Pharmaceutical Co., Ltd. Process for producing purinone derivative
JP6979877B2 (ja) * 2015-06-08 2021-12-15 デビオファーム インターナショナル， エス． アー． 抗ｃｄ３７イムノコンジュゲートおよび抗ｃｄ２０抗体の組み合わせ
CR20170562A (es) 2015-06-24 2018-02-01 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad diseñada.
WO2017040247A1 (en) 2015-08-28 2017-03-09 Immunogen, Inc. Antibodies and assays for detection of cd37
WO2017059224A2 (en) * 2015-10-01 2017-04-06 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
JP2018534263A (ja) * 2015-10-02 2018-11-22 ギリアード サイエンシーズ， インコーポレイテッド 癌、アレルギー性障害、自己免疫性疾患または炎症性疾患を治療するための、ｊａｋ阻害物質、ａｓｋ１阻害物質、ｂｒｄ阻害物質及び／またはｍｍｐ９阻害物質から選択される阻害物質とｂｔｋ阻害物質ｇｓ−４０５９の組み合わせ
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
EP3356406A1 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
EP3535297B1 (en) 2016-11-02 2022-08-10 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
CN110869391A (zh) * 2017-07-26 2020-03-06 豪夫迈·罗氏有限公司 用BET抑制剂,Bcl-2抑制剂和抗CD20抗体的组合疗法
TW202323297A (zh) 2017-08-08 2023-06-16 瑞士商赫孚孟拉羅股份公司 新穎ＤＬＢＣＬ病患次族群之歐比托珠單抗（ｏｂｉｎｕｔｕｚｕｍａｂ）治療
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1034298T3 (da) * 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
EP3284753B1 (en) * 2002-10-17 2019-06-05 Genmab A/S Human monoclonal antibodies against cd20 for use in the treatment of multiple sclerosis
ME00973B (me) * 2007-07-31 2012-06-20 Regeneron Pharma Humana antitjela prema humanom cd20 i postupak njihovog korišćenja
TWI535716B (zh) * 2010-05-31 2016-06-01 Ono Pharmaceutical Co Purine ketone derivatives
EA032463B1 (ru) * 2011-10-19 2019-05-31 Фармасайкликс Элэлси Применение ингибиторов тирозинкиназы брутона (втк)
US20130302274A1 (en) * 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
NZ626750A (en) * 2011-11-29 2015-08-28 Ono Pharmaceutical Co Purinone derivative hydrochloride
WO2014081712A2 (en) * 2012-11-20 2014-05-30 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with bruton's tyrosine kinase

Also Published As

Publication number Publication date
JP6478989B2 (ja) 2019-03-06
TW201521767A (zh) 2015-06-16
JP2016536298A (ja) 2016-11-24
RU2727650C2 (ru) 2020-07-22
PL3066126T3 (pl) 2019-08-30
MY178726A (en) 2020-10-20
RU2016122232A3 (tr) 2018-06-18
CN113995843A (zh) 2022-02-01
BR112016010271A2 (pt) 2017-10-03
CN105792846A (zh) 2016-07-20
RU2016122232A (ru) 2017-12-08
IL244960A0 (en) 2016-05-31
IL244960B (en) 2021-08-31
TWI524899B (zh) 2016-03-11
EP3066126A2 (en) 2016-09-14
KR20160079869A (ko) 2016-07-06
NZ718792A (en) 2020-05-29
CN114632158A (zh) 2022-06-17
CA2926893C (en) 2022-04-12
CA2926893A1 (en) 2015-05-14
HK1222803A1 (zh) 2017-07-14
AR098328A1 (es) 2016-05-26
AU2014345712A1 (en) 2016-05-05
WO2015067586A2 (en) 2015-05-14
PH12016500839A1 (en) 2016-06-13
EP3066126B1 (en) 2019-03-27
AU2014345712B2 (en) 2019-10-17
US20200171153A1 (en) 2020-06-04
ES2728350T3 (es) 2019-10-23
WO2015067586A3 (en) 2015-07-30
US20150125446A1 (en) 2015-05-07
MX2016005801A (es) 2016-11-29
KR101874215B1 (ko) 2018-07-03

Similar Documents

Publication Publication Date Title
TR201907240T4 (tr) Bir anti cd20 antikorunun bir btk inhibitörü ile kombinasyon tedavisi.
CY1126115T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
CY1123433T1 (el) Αιθερες αρυλιου και χρησεις εξ αυτων
CY1119287T1 (el) Συζευγματα αντισωματων πυρρολοβενζοδιαζεπινης-αντι-her2
CY1119782T1 (el) Συζευγματα πυρρολοβενζοδιαζεπινης-αντισωματος αντι-cd22
CY1119251T1 (el) Θεραπεια συνδυασμου ενος αφουκοζυλιωμενου αντισωματος cd20 με μπενδαμουστινη
AR096183A1 (es) Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-fármaco
TN2015000396A1 (en) Antibody drug conjugates
CL2016001586A1 (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
MX2016003744A (es) Anticuerpos tem8 y su uso.
BR112017001588A2 (pt) conjugados de anticorpo/fármaco anti-cdh6
CR20150284A (es) Terapia de combinación de anticuerpos anti-her3 y anti-her2
MX2013006739A (es) Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2.
CR20170529A (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2.
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
CY1121821T1 (el) Θεραπεια συνδυασμου για την αγωγη του καρκινου των ωοθηκων
CL2017003295A1 (es) Anticuerpos contra csf-1r humano para su uso en la inducción de linfocitosis en linfomas o leucemias
NZ711867A (en) Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate
EA201591304A1 (ru) Применение комплекса, облегчающего транскрипцию хроматина (fact), при раке
BR112014028507A2 (pt) anticorpos cd33 e uso dos mesmos para tratar câncer